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Circulating Klotho levels: clinical
relevance and relationship with
tissue Klotho expression
Tilman B. Dru¨eke1 and Ziad A. Massy1,2
Klotho is a protein that exerts paracrine and endocrine functions.
In chronic kidney disease (CKD), its expression is decreased in several
tissues. This decrease probably plays important roles in various
complications associated with CKD, in both a fibroblast growth
factor-23 (FGF23)-dependent and an FGF23-independent manner.
The clinical diagnosis of Klotho deficiency is not easy. The relevance
of circulating Klotho levels, if any, needs to be adequately defined.
Serum Klotho may not reflect tissue Klotho concentration.
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The unraveling of the respective roles of
Klotho and fibroblast growth factor-23
(FGF23) occupies at present a major
place in both experimental and clinical
research devoted to the mineral and
bone disorder of chronic kidney disease
(CKD-MBD) and to disturbances of
bone and mineral metabolism in other
disease states.
Klotho, or more precisely a-Klotho,
is a single-pass transmembrane protein
that is expressed predominantly in
kidney tubular epithelium, and to a
lesser extent in the parathyroid gland
and epithelial cells of the choroid
plexus. The protein has a large extra-
cellular amino-terminal domain and a
small intracellular carboxy-terminal
domain. The extracellular domain is
made of two internal repeat sequences,
named KL1 and KL2.1 Circulating
Klotho results either from direct
secretion by the cell or from cleavage
of the intracellular domain of the full-
length protein by secretases. Both
processes lead to ‘soluble Klotho,’
which is found in blood, urine, and
cerebrospinal fluid.2
It was believed for some time that
Klotho functioned mainly, if not un-
iquely, as a coreceptor for FGF23
binding to FGF receptor 1 (FGFR1),
and that this cooperativity function was
restricted to the ectodomain of mem-
brane Klotho. Although FGFRs have a
much lower affinity for the isolated
Klotho ectodomain than for the full-
length transmembrane form, the rela-
tive importance of membrane and
soluble Klotho in this interaction re-
mains elusive.2 It is clearly established
at present that Klotho exerts both
FGF23-dependent and FGF23-indepen-
dent, pleiotropic actions. Soluble
Klotho acts as both a paracrine and
an endocrine factor.3
Its paracrine functions include reg-
ulation of the surface abundance of the
tubular Ca2þ channel TRPV5 and Kþ
channel ROMK in that Klotho is a
glycosidase removing sialic acids from
N-glycan.1 Notably, soluble Klotho also
has been shown to inhibit sodium
phosphate (NaPi) cotransporters in
renal opossum kidney cells and in
cell-free membrane vesicles in vitro in
the absence of FGF23. Moreover,
exogenously administered Klotho
resulted in decreased renal expression
of NaPi-2a and hypophosphatemia in
FGF23-null mice in vivo, demonstrating
that Klotho can induce hyperphos-
phaturia independently of FGF23.4
Finally, soluble Klotho also inhibits
intestinal NaPi-2b transporters, as
shown in NaPi-2b-expressing oocytes.5
As a hormone, Klotho targets
multiple remote tissues and organs.
These actions comprise anti-aging and
cardiovascular protective properties.
Klotho reduces oxidative stress by the
inhibition of insulin and insulin-
like growth factor-1 signaling path-
ways. It enhances endothelial nitric
oxide production and thereby improves
endothelium-dependent vasodilata-
tion.6 It is an endogenous inhibitor
of vascular calcification, as shown
in recent studies in vitro and in
CKD mice in vivo. Finally, it decreases
cell-surface abundance of the Ca2þ
channel TRPC6. This channel is
expressed in cardiac, glomerular, and
vascular smooth muscle cells and plays
an important role in the regulation of
vascular resistance and blood pressure.1
Since upregulation of TRPC6 is
implicated in the pathogenesis of
cardiac hypertrophy and glomerulo-
sclerosis, downregulation of its express-
ion by Klotho should be protective
against these disease conditions.
At the cellular level, the antioxidant
actions of Klotho include the induction
of resistance to H2O2 and suppression of
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lipid peroxidation through activation of
the FOXO family of transcription factors
and stimulation of manganese super-
oxide dismutase.2 Klotho inhibits cell sen-
escence and apoptosis. Further, Klotho
protects against renal fibrosis.2,7 It also
promotes kidney regeneration after
ischemia–reperfusion injury via the
suppression of fibrosis-promoting growth
factors, the preservation of stem cells, and
the recovery of endothelial integrity and
function, respectively.2 Figure 1 reflects
the present understanding of the inter-
actions of Klotho and FGF23 with
calcium, phosphate, parathyroid hormone
(PTH), and vitamin D metabolism.
In CKD, the expression of Klotho
is decreased in various tissues. In the
human kidney, decreased Klotho
expression occurs as early as in
CKD stage 2. This decrease could be
responsible, at least in part, for the
early increase in serum FGF23.8 In the
parathyroid tissue of patients
with more advanced stages of CKD,
reduced Klotho expression, together
with reduced FGFR1 expression, is
believed to explain the resistance to
the inhibitory action of FGF23.9 The
vascular smooth muscle of patients
with CKD also displays a state of
Klotho deficiency.10 Klotho knock-
down potentiates the development of
accelerated calcification through a
Runx2- and myocardin/serum response
factor-dependent pathway, and restora-
tion of Klotho expression in vascular
cells allows FGF23 and calcitriol to
exert anticalcifying effects.
Why is tissue Klotho decreased in
CKD? Current explanations include
hyperphosphatemia and hypercalcemia,
a proinflammatory state, and uremic
toxins as potential culprits. The latter
can cause epigenetic modification of
specific genes, potentially resulting
from increased DNA methyltransferase
expression and DNA hypermethylation.
This hypothesis is based on the ob-
servation that uremic toxins such as
indoxyl sulfate or p-cresyl sulfate sti-
mulate DNA methyltransferase and
decrease Klotho expression in vitro,
and that specific inhibition of DNA
methyltransferase activity increases
Klotho expression.11
An important question is whether in
patients with CKD the concentration of
soluble Klotho in the circulation re-
flects Klotho deficiency at the tissue
level. Seiler et al.12 (this issue) now
address this question in detail. First
of all, they point out that existing
literature is inconclusive. Yamazaki
et al.13 found correlations of serum
Klotho with age and serum levels of
creatinine, phosphorus, and FGF23.
They also observed higher levels in
children than in adult people. Several
cross-sectional, observational studies
were carried out subsequently, with
contradictory results as to a possible
link between circulating Klotho and
kidney function. Second, Seiler et al.12
stress the fact that a reliable measure-
ment of circulating Klotho has become
available only recently, with the advent
of a sensitive and specific enzyme-
linked immunosorbent assay.13 Third,
they report their own findings in a large
cohort of patients with CKD stages 2–4,
with a follow-up of approximately 2
years. They find a significant correla-
tion of plasma Klotho with age, but not
with estimated glomerular filtration
rate or other parameters of CKD-
MBD, including plasma PTH, plasma
FGF23, and fractional excretion of
phosphorus (FePi). In contrast, they
confirm previous observations of sig-
nificant increases in these three para-
meters with declining kidney function,
and significant correlations of circulat-
ing FGF23 with plasma PTH, plasma
phosphorus, and FePi. Finally, by Cox
regression analysis, plasma FGF23,
plasma PTH, and FePi, but not plasma
Klotho, are predictive of adverse patient
outcomes (combined end point) in uni-
variate analysis. FGF23, but not PTH or
FePi, remains an independent predictor
of adverse patient outcomes after adjust-
ment for age, estimated glomerular filtra-
tion rate, and albuminuria.
The failure to observe an association
between plasma Klotho and estimated
glomerular filtration rate could be due
to the fact that patients with late CKD
stages were excluded from this analysis.
In a recent study by Yokoyama et al.14
serum Klotho was significantly lower
in chronic hemodialysis patients than
in healthy controls, and it displayed
a positive correlation with serum
phosphorus. The lack of a healthy
control subject group in the study by
Seiler et al.12 somewhat complicates the
interpretation of the results. It remains
possible that CKD patients have lower
plasma Klotho levels than healthy
controls from CKD stage 2 onward,
with no further decrease with the
progression to CKD stages 3 and 4. In



















Figure 1 | Involvement of tissue and circulating Klotho in mineral metabolism: a
schematic view. Calcitriol, 1,25-dihydroxyvitamin D; PTH, parathyroid hormone; TRPV5,
highly selective renal Ca2þ entry channel; ROMK, renal Kþ channel; NaPi-2a, renal sodium/
phosphate cotransporter; NaPi-2b, intestinal sodium/phosphate cotransporter; TRPC6,
ubiquitous Ca2þ entry channel.
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found a decrease in urinary and plasma
Klotho levels in mice with early CKD.15
Notably, the normal circulating levels of
Klotho reported by Yamazaki et al.13
have been determined in serum, not in
plasma, in healthy Asian volunteers,
which may not precisely reflect plasma
Klotho levels in European controls. It
also is surprising that Seiler et al.12 fail
to identify circulating phosphorus as
an independent predictor of adverse
outcomes, in contrast to many previous
reports both in patients with CKD and
in the general population without
known kidney impairment, where
even only slight elevations of serum
phosphorus were predictive of higher
mortality risk. Seiler et al.12 do not
provide information on the vitamin D
status of their patients. There might
be a difference in plasma Klotho levels
between vitamin D-replete and vitamin
D-deficient CKD patients, since active
vitamin sterols increase tissue Klotho
expression.10 Finally, the absence of
changes in plasma Klotho with the
progression of CKD and the absence
of correlations with other biochemical
parameters in the study by Seiler et al.12
certainly do not preclude a potentially
major role of Klotho at the organ and/
or patient-outcome level. Other exam-
ples of a dissociation between tissue
and plasma levels are tissue growth
factors such as transforming growth
factor (TGF)-a and TGF-b and bone
morphogenetic proteins. Unfortunately,
quantification of membrane-bound
Klotho at the tissue or cellular level in
humans is not feasible for large epide-
miological studies, as Seiler et al.12 point
out. Therefore, further evaluation of
circulating Klotho levels in the general
population and in CKD patients is
warranted.
In conclusion, on the basis of the
present state of knowledge, Klotho
measurement in the circulation does
not appear to be a useful tool in
patients with CKD, but additional
studies are still needed. The precise
understanding of the relative roles of
FGF23-dependent and FGF23-indepen-
dent Klotho actions also requires
further study. Figure 2 shows a hypo-
thetical scheme of the complex condi-
tion of FGF23 excess and Klotho
deficiency in CKD, in interplay with
high serum calcium and phosphorus
levels and the response to active
vitamin D sterol administration via an
increase in serum 1,25 dihydroxy vita-
min D concentration.
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Figure 2 | Hypothetical scheme of the complex condition of FGF23 excess and Klotho
deficiency in chronic kidney disease. Interplay with high serum calcium and phosphorus
levels and the response to active vitamin D sterol administration via an increase in serum 1,25
dihydroxy vitamin D levels.16 LVH, left ventricular hypertrophy.
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